Shares of Alvotech (NASDAQ: ALVO) tumbled 7.68% in Wednesday's trading session following the company's disappointing third-quarter earnings report and reduced full-year guidance. The Iceland-based biosimilars developer faced multiple headwinds that contributed to investor concerns and the subsequent stock decline.

Alvotech reported Q3 revenue of $113.744 million, falling short of analyst expectations of $117.203 million. While this represents a 10.55% increase from the same period last year, the miss raised concerns about the company's growth trajectory. More significantly, Alvotech lowered its full-year 2025 revenue guidance to a range of $570-$600 million, down from previous estimates. The company also reduced its adjusted EBITDA forecast to $130-$150 million, further dampening investor sentiment.

Adding to the pressure on Alvotech's stock was the ongoing issue stemming from an FDA inspection of its Reykjavik facility in July. The company emphasized that resolving these regulatory matters is a "top priority," but the unresolved status continues to weigh on investor confidence. Furthermore, Alvotech's cash position decreased to $42.8 million as of September 30, driven by inventory build-up for new launches, capital expenditures, and recent acquisitions. While the company secured a new $100 million working capital option, the cash burn rate remains a concern for some investors. These factors collectively contributed to the sharp decline in Alvotech's stock price, reflecting market apprehension about the company's near-term prospects and regulatory challenges.